What Dianthus Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 30 | 66 |
| Total trades | 43 | 107 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 257,429 | 978,851 |
| Disposed | 242,429 | 898,559 |
| Net activity | +15,000 | +80,292 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −700 | $104.39 | −$73.1K | 0 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −1,100 | $103.20 | −$114K | 700 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −3,501 | $102.39 | −$358K | 1,800 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −6,771 | $101.37 | −$686K | 5,301 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Open-market sale · S | −7,928 | $100.43 | −$796K | 12,072 |
| Carr Edward | CHIEF ACCOUNTING OFFICER | Sep 17 | Exercise / conversion · M | +20,000 | $17.88 | +$358K | 20,000 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Open-market sale · S | −13,309 | $106.74 | −$1.42M | 4,000 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Open-market sale · S | −7,215 | $106.25 | −$767K | 17,309 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Open-market sale · S | −2,600 | $105.19 | −$273K | 24,524 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Exercise / conversion · M | +9,375 | $22.07 | +$207K | 27,124 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Exercise / conversion · M | +6,249 | $21.77 | +$136K | 17,749 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 | Exercise / conversion · M | +7,500 | $17.88 | +$134K | 11,500 |
| Read Simon | Director | Aug 19 | Open-market sale · S | −2,778 | $117.55 | −$327K | 0 |
| Read Simon | Director | Aug 19 | Exercise / conversion · M | +2,778 | $18.36 | +$51K | 2,778 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 13 | Exercise / conversion · M | +15,000 | $18.17 | +$273K | 15,000 |
| Read Simon | Director | Aug 10 | Open-market sale · S | −397 | $111.77 | −$44.4K | 0 |
| Read Simon | Director | Aug 10 | Open-market sale · S | −470 | $111.05 | −$52.2K | 397 |
| Read Simon | Director | Aug 10 | Open-market sale · S | −272 | $109.96 | −$29.9K | 867 |
| Read Simon | Director | Aug 10 | Open-market sale · S | −831 | $108.95 | −$90.5K | 1,139 |
| Read Simon | Director | Aug 10 | Open-market sale · S | −737 | $108.17 | −$79.7K | 1,970 |
Loading...
